CTSA Program Posters

BACKGROUND Researchers have had to explore new modes of patient identification and recruitment due to the restrictions and resource limitations caused by the COVID-19 pandemic. Electronic health record (EHR)-based participant identification and recruitment through patient portal messaging offer potential solutions to help researchers meet recruitment goals without the additional risk of in-person

The Institute for Translational Medicine (ITM) aims to make research breakthroughs happen and to put those discoveries into the real world to improve health. The ITM is a partnership between the University of Chicago and Rush in collaboration with Advocate Health Care, the Illinois Institute of Technology, Loyola University Chicago, and NorthShore University HealthSystem. The goal of the ITM

The Trial Innovation Network (TIN) is an established partnership with the CTSA Program, the National Center for Advancing Translational Science (NCATS), and other NIH Institutes and Centers. Currently (AUG 2019) the TIN is supporting 212 projects, including 134 active studies that represent 59 therapeutic areas. These projects create opportunities for the CTSA Program Hubs, the Trial Innovation

Introduction The COVID-19 pandemic has claimed over 220,000 lives in the United States. A promising resource for discovery in COVID-19’s symptom progress is data documented in electronic health record (EHR) systems as part of clinical care. Such data are stored in disparate locations within the EHR, requiring multiple extraction methods. Methods Symptoms were extracted from EHR data for all

The Ohio State University CCTS is developing a comprehensive support system for researchers to work with existing datasets through data curation and access, financial support for innovative research ideas, and education about practical data issues and challenges.

This poster outlines and explains the purpose, strategies, and results associated with the VaccinateLA initiative, an interdisciplinary, multimedia health campaign designed to improve vaccination rates in high-disparity communities around Los Angeles, California.

The Center for Innovative Drug Discovery (CIDD), a joint-venture between the University of Texas Health at San Antonio (UTHealthSA) and the University of Texas at San Antonio (UTSA), provides core-based services that support biomedical research related to drug discovery. The primary goal of CIDD is to provide a diverse array of technologies and expertise to enable the translation of basic

UICentre is a campus-wide small molecule drug discovery initiative at the University of Illinois at Chicago associated with the Center for Clinical and Translational Sciences (CTSA). Using established core instrumentation and with modest annual support, UICentre was conceived to utilize existing resources to leverage the expertise of scientist and clinicians teams across campus in collaborative

Racial/ethnic minority, low socioeconomic status (SES) and rural populations suffer profound health inequities across a wide variety of diseases and conditions, as well as a disproportionate burden of the negative health consequences of the COVID-19 pandemic. Latinos make up ~14% of the Utah population compared to ~28 of Utah’s COVID-19 cases, and the case rate is over 3-fold higher in

Clinical and research data are increasingly collected and aggregated in clinical data warehouses (CDWs). Access to these data is subject to local, state and national regulations. For multiple reasons, institutions differ in how they interpret and apply these regulations. Sometimes, inter-institutional differences are unavoidable, such as when regulations clearly require specific practices. However